- $557.60m
- $414.05m
- 41
- 20
- 89
- 48
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.99 | ||
| Price to Tang. Book | 3.99 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -37.41% | ||
| Return on Equity | -46.63% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 5.04 | 11.66 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.
Directors
- Brian Sullivan CHM (59)
- Lance Laing CFD (59)
- Vicky Hahne CFO (55)
- Richard Buller IND (71)
- David Dalvey IND (62)
- Leo Furcht IND (74)
- Richard Nigon IND (73)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 15th, 2017
- Public Since
- September 20th, 2017
- No. of Shareholders
- 55
- No. of Employees
- 55
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 30,453,120
- Address
- 16305 36th Ave N Ste 100, MINNEAPOLIS, 55446-4285
- Web
- https://www.celcuity.com/
- Phone
- +1 7633920767
- Auditors
- Boulay PLLP
Upcoming Events for CELC
Celcuity Inc Annual Shareholders Meeting
Celcuity Inc Annual Shareholders Meeting
Q1 2024 Celcuity Inc Earnings Release
Q2 2024 Celcuity Inc Earnings Release
Similar to CELC
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Celcuity share price?
As of Today at 19:05 UTC, shares in Celcuity are trading at $18.31. This share price information is delayed by 15 minutes.
How has the Celcuity share price performed this year?
Shares in Celcuity last closed at $18.31 and the price had moved by +87.79% over the past 365 days. In terms of relative price strength the Celcuity share price has outperformed the S&P500 Index by +51.66% over the past year.
What are the analyst and broker recommendations for Celcuity?
The overall consensus recommendation for Celcuity is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Celcuity dividend yield?
Celcuity does not currently pay a dividend.
Does Celcuity pay a dividend?
Celcuity does not currently pay a dividend.
When does Celcuity next pay dividends?
Celcuity does not currently pay a dividend.
How do I buy Celcuity shares?
To buy shares in Celcuity you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Celcuity?
As of the previous close price of $18.31, shares in Celcuity had a market capitalisation of $557.60m.
Where are Celcuity shares listed?
Here are the trading details for Celcuity:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CELC
What kind of share is Celcuity?
Based on an overall assessment of its quality, value and momentum Celcuity is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Celcuity share price forecast for 2024?
The analyst consensus target price for shares in Celcuity is $28.60. That is 56.2% above the last closing price of $18.31.
Analysts covering Celcuity currently have a consensus Earnings Per Share (EPS) forecast of -$2.92 for the next financial year.
What is the trend in the Celcuity share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Celcuity. Over the past six months, its share price has outperformed the S&P500 Index by +57.09%.
As of the last closing price of $18.31, shares in Celcuity were trading +41.65% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Celcuity PE Ratio?
The Celcuity PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $18.31.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Celcuity?
Celcuity's management team is headed by:
- Brian Sullivan - CHM
- Lance Laing - CFD
- Vicky Hahne - CFO
- Richard Buller - IND
- David Dalvey - IND
- Leo Furcht - IND
- Richard Nigon - IND